The motivation of at-risk individuals and their partners in deciding for or against predictive testing for Huntington's disease

2008 ◽  
Vol 35 (1) ◽  
pp. 29-40 ◽  
Author(s):  
G. Evers-Kiebooms ◽  
A. Swerts ◽  
J. J. Cassiman ◽  
H. Van Den Berghe
2002 ◽  
Vol 32 (3) ◽  
pp. 39-47
Author(s):  
M.D. Lucas ◽  
O. H. Turnbull ◽  
M. Berk ◽  
V.U. Fritz

The discovery of a polymorphic DNA marker for Huntington's Disease (HD) in 1983, and the specific gene responsible in 1993, led to predictive testing programmes out of which came research into whether or not cognitive impairment was present presymptomatically in those at risk for HD. The results of these studies have been conflicting and inconclusive. Methodoiogical limitations have probably contributed to the differing findings. The present study attempted to expand upon previous studies by analysing the data in a more comprehensive manner, and with additional control conditions. In this study, 26 individuals, at risk but presymptomatic, for HD were recruited from the Johannesburg Predictive Testing Programme and administered a battery of psychological tests prior to molecular analysis. Of this HD group, 11 were subsequently positive for the gene (the HD+ group) and 15 were negative (HD- group). A carefully chosen control group, (matched for age, sex, and education - Control Group 1) and a group of individuals experiencing a life threatening medical illness (without CNS involvement - Control Group 2) were administered the same battery of psychological tests. Four-way Analysis of Variance between the HD+, HD-, and Control groups was conducted to detect specific differences between the groups. The results indicated that the HD+ group showed mild impairment for declarative memory function. However, it would appear that undergoing the psychological evaluation itself impacted upon the test performance of both the HD+ and HD- groups.


1990 ◽  
Vol 28 (5) ◽  
pp. 614-621 ◽  
Author(s):  
Scott T. Grafton ◽  
John C. Mazziotta ◽  
Jorg J. Pahl ◽  
Peter St. George-Hyslop ◽  
Jonathan L. Haines ◽  
...  

2018 ◽  
Vol 7 (4) ◽  
pp. 391-402 ◽  
Author(s):  
Miranda F. Lewit-Mendes ◽  
Georgia C. Lowe ◽  
Sharon Lewis ◽  
Louise A. Corben ◽  
Martin B. Delatycki

2021 ◽  
Vol 11 (8) ◽  
pp. 815
Author(s):  
Filipa Júlio ◽  
Ruth Blanco ◽  
Josè Perez Casanova ◽  
Barbara D’Alessio ◽  
Beatrice De Schepper ◽  
...  

There has been great progress in Huntington’s disease (HD) research. Yet, effective treatments to halt disease before the onset of disabling symptoms are still unavailable. Scientific breakthroughs require an active and lasting commitment from families. However, they are traditionally less involved and heard in studies. Accordingly, the European Huntington Association (EHA) surveyed individuals at risk (HDRisk) and with premanifest HD (PreHD) to determine which factors affect their willingness to participate in research. Questions assessed research experience and knowledge, information sources, reasons for involvement and noninvolvement, and factors preventing and facilitating participation. The survey included 525 individuals, of which 68.8% never participated in studies and 38.6% reported limited research knowledge. Furthermore, 52% trusted patient organizations to get research information. Reasons for involvement were altruistic and more important than reasons for noninvolvement, which were related to negative emotions. Obstacles included time/financial constraints and invasive procedures, while professional support was seen as a facilitator. PreHD individuals reported less obstacles to research participation than HDRisk individuals. Overall, a high motivation to participate in research was noted, despite limited experience and literacy. This motivation is influenced by subjective and objective factors and, importantly, by HD status. Patient organizations have a key role in fostering motivation through education and support.


Sign in / Sign up

Export Citation Format

Share Document